Century Therapeutics, Inc.

Century Therapeutics, Inc. is a biotechnology company focused on developing allogeneic cell therapies for solid tumors, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for type 1 diabetes. The company is also developing CNTY-308, a CD19-targeted CAR-iT cell therapy for B-cell-mediated autoimmune diseases, and CNTY-101, an allogeneic iPSC-derived CAR-iNK cell therapy with six precision gene edits targeting CD19 for B-cell mediated autoimmune diseases. These therapies are designed to evade the immune system and provide off-the-shelf treatments.

Century Therapeutics, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol IPSC. Its shares are traded in United States Dollars (USD). The NasdaqCM is a US-based stock exchange that typically lists smaller-capitalization companies. Investors can buy and sell IPSC shares during regular trading hours on this exchange.

Century Therapeutics operates in the Healthcare sector and specifically within the Biotechnology industry. As a biotechnology company, it focuses on using living cells and biological processes to develop therapies. Its work involves genetic engineering of induced pluripotent stem cells (iPSCs) to create allogeneic cell therapies, which are treatments derived from donor cells that can be used in multiple patients without the need for personalized matching.

Century Therapeutics, Inc. is headquartered in Philadelphia, Pennsylvania, United States. The company was incorporated in 2018. Being based in Philadelphia places it within a major US biotech hub, which provides access to research talent and partnerships. Its location in the United States also means it operates under US regulatory frameworks, including the FDA, for the development and approval of its cell therapy products.